Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background: The efficacy of esketamine nasal spray for treatment-resistant depression remains controversial. This systematic review and meta-analysis was conducted to explore the influence of esketamine nasal spray on treatment efficacy for treatment-resistant depression. Methods: We conducted a comprehensive search across multiple databases, including PubMed, EMbase, Web of Science, EBSCO, and Cochrane library through March 2024 for randomized controlled trials (RCTs) assessing the effect of esketamine nasal spray on the treatment efficacy of depression. This meta-analysis was performed using the random-effect model. Results: Five RCTs are included in the meta-analysis. Overall, compared with control group treatment-resistant depression, esketamine nasal spray is associated with significantly reduced MADRS scores (SMD = −3.88; 95% confidence interval [CI] = −5.71 to −2.05; P < .0001), increased response rates (RR = 1.99; 95% CI = 1.28–3.10; P = .002), decreased Sheehan Disability Scale (SMD = −3.01; 95% CI = −4.39 to −1.64; P < .0001) and PHQ-9 scores (SMD = −2.32; 95% CI = −3.51 to −1.13; P = .0001), but leads to the increase in dizziness (RR = 3.55; 95% CI = 2.37–5.32; P < .00001) and nausea (RR = 3.88; 95% CI = 2.10–7.18; P < .0001). Conclusion: Esketamine nasal spray is beneficial to improve the efficacy of treatment-resistant depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, uncertainty persists regarding (i) consistency of short-term efficacy across induction trials (including older adults), (ii) durability of benefit during maintenance and relapse prevention, (iii) comparative impact on functional outcomes, and (iv) the frequency and clinical relevance of key adverse events and discontinuations.”
From Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis (2026) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple evidence syntheses of esketamine have been published, generally indicating statistically significant symptom improvement versus placebo but raising questions about clinical magnitude, heterogeneity across trials and populations, and trade-offs in adverse events (26–28).”
From Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis (2026) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent secondary evidence has likewise concluded that intranasal esketamine improves depressive symptoms and response outcomes in TRD while increasing acute adverse effects such as dizziness and nausea, which is consistent with our safety synthesis (26–28)”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“[20] Each element is assigned one point if adequately described and conducted in the original study, and additional points are awarded for specific methodological rigor.”
Depression in Late Life: Review and Commentary
Blazer, D. G. (2003) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/58.3.m249 · Cited by 2,344
Kjaergard, L. L., Villumsen, J., & Gluud, C. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,283
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 4×
“[16,17] Our meta-analysis confirms that the addition of esketamine nasal spray significantly reduces MADRS scores and improves response rates in patients with treatment-resistant depression.”
InfluentialDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · cited 2×
“17 , 23 ] 3.”
InfluentialFedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Cited by
Ammendolia, I., Mannucci, C., Esposito, E., Calapai, G., Currò, M., Midiri, P., Mondello, C., Cardia, L., & Calapai, F. (2025) · Pharmaceuticals · doi:10.3390/ph18050702 · Cited by 8
An, J., Li, X., Li, Z., Wang, J., & Pan, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04417-y · Cited by 5
Ketamine pharmacotherapy for major depressive disorder: A narrative review
Miller, C. H., Hickman, A., Baten, C., Ali, Z., Kahlon, S. K., Klassen, A. M., Zamora, G., Shepherd, J. H., Venegas, G., Miller, J. A., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111651 · Cited by 3
Xie, J., Pu, C., & Sun, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1774549 · Cited by 1
Liu, Y., Liu, X., Olbrich, S., Lao, C.-L., Zhang, H., Brunovský, M., & Ip, C.-T. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261462240 · Cited by 1
Metadata
- Authors
- Ouyang, Y., & Li, J.
- Affiliations
- The University of Queensland (AU)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Corresponding author
- Li, Juan
- Venue
- Medicine
- Published
- 2025-02-28
- Volume
- 104
- Issue
- 9
- Pages
- e41495
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC11875627
- OpenAlex
- W4408030617
- Cited by
- 10
- References
- 24
- Citations by year
- 2026: 8 · 2025: 2
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, nasal spray, treatment-resistant depression, antidepressant efficacy, Montgomery-Asberg Depression Rating Scale, Sheehan Disability Scale, PHQ-9, adverse effects, dizziness, nausea
- MeSH terms
- Administration, Intranasal, Antidepressive Agents, Humans, Ketamine, Randomized Controlled Trials as Topic, Treatment Outcome, Nasal Sprays, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies. https://app.cochat.ai/papers/10.1097/md.0000000000041495
- The paper
- Ouyang, Y., & Li, J. (2025). Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies. Medicine. https://doi.org/10.1097/md.0000000000041495
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.